Jasper Therapeutics Inc. has released a corporate presentation detailing the clinical progress and therapeutic strategy of their investigational drug, briquilimab. The presentation highlights briquilimab's potential in treating mast cell-driven diseases through KIT inhibition, which has shown to significantly deplete mast cells for durable and well-tolerated disease control. Clinical studies, such as BEACON and SPOTLIGHT, demonstrate briquilimab's rapid onset and high response rates in conditions like chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). The ongoing ETESIAN study for asthma and evaluations in other mast cell-mediated diseases further emphasize the drug's potential franchise expansion. Briquilimab, not yet approved for any indication, continues to show promise in various clinical studies. You can access the full presentation through the link below.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。